$IMTX positive clinical data update from Phase 1 trials
Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs
·First anti-tumor activity observed in heavily pre-treated solid cancer patients during early phases of dose escalation
·Tumor shrinkage observed in 8 out of 10 patients including one partial response consistent with robust biological activity of infused T cell products
·Treatment-emergent adverse events were transient and manageable
finance.yahoo.com/news/immatics-presents-data-dose-escalation-110000980.html
·First anti-tumor activity observed in heavily pre-treated solid cancer patients during early phases of dose escalation
·Tumor shrinkage observed in 8 out of 10 patients including one partial response consistent with robust biological activity of infused T cell products
·Treatment-emergent adverse events were transient and manageable
finance.yahoo.com/news/immatics-presents-data-dose-escalation-110000980.html
免责声明
这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。